Articles tagged with Growth Factor Receptors
The phase Ia/Ib Beamion LUNG-1 trial found that zongertinib elicited durable responses in patients with advanced, previously treated non-small cell lung cancer (NSCLC) harboring a HER2 mutation. The disease control rate was high across cohorts, with median progression-free survival ranging from 12.4 to 6.8 months.
A cohort study found that women with screen-detected estrogen receptor–positive or human epidermal growth factor receptor 2–negative breast cancer who underwent prior screening had an earlier stage of diagnosis and lower breast cancer mortality compared to those who did not undergo prior screening.
Scientists designed ring-shaped proteins targeting growth factor receptors to control human stem cell development. The resulting vascular networks formed tubes, healed, and absorbed nutrients, offering a new approach to repairing damaged hearts and kidneys.
Researchers investigated combining Sacituzumab govitecan with platinum-based chemotherapeutics for triple-negative breast cancer, urinary bladder carcinoma, and small-cell lung carcinoma. The study showed additive to synergistic antitumor effects in vitro and in vivo, with improved outcomes in tumor-bearing animals.
A Boston College biologist is studying the mechanisms of viral insulins to develop novel therapeutics for a range of human diseases, including cancers. The researcher has identified six viruses that mimic human insulin and IGF-1, which can block an important receptor, leading to potential affordable treatments.
A novel three-drug combination of an HDAC inhibitor with two types of immunotherapy achieved a 25% overall response rate and 50% progression-free survival in women with advanced HER2-negative breast cancer. Patients with triple-negative breast cancer had a higher response rate, highlighting the need for further clinical evaluation.
A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to HER2-targeted treatment in HER2-positive metastatic breast cancer patients. Whole-body PET/CT enables quantification of HER2 expression and predicts metabolic response, potentially sparing patients from unnecessary side effects.
Researchers identified distinct genomic characteristics that impact prognosis for patients with triple negative apocrine carcinoma. The study confirmed a five-year disease-free survival rate of 92.2% for these patients, significantly higher than those diagnosed with other types of TNBC.
Researchers found that verapamil prevents the decline of insulin-like growth factor 1 (IGF-1) in Type 1 diabetes patients and promotes IGF-1 signaling in pancreatic beta cells. This mechanism may contribute to the beneficial effects of verapamil on preserving beta-cell function in Type 1 diabetes.
A new study found that cetuximab plus radiotherapy is an active treatment option for locally advanced cutaneous squamous cell skin cancer, with an objective response rate of 83.2%. The treatment was well-tolerated, with most patients experiencing mild acneiform skin rash or fatigue.
Researchers from Rice University and Princeton University have developed a new technology that allows for the live monitoring of signaling protein networks in living cells. The 'live reporter' system uses unobtrusive proteins to tag specific proteins, which can activate fluorescent markers when they become phosphorylated.
Inflammatory breast cancer is a rare and aggressive form of breast cancer with poor outcomes. Research highlights the role of ERβ as a mediator of estrogen signaling, demonstrating its tumor suppressive effects in preclinical models. ERβ's antimetastatic activity may hold promise for improving treatment options for IBC.
Researchers have identified opioid growth factor receptor (OGFr) as a promising new target for enhancing lipid oxidation. Studies in rodents and human subjects suggest that OGFr boosts lipid metabolism, improving thermogenesis and reducing the risk of obesity-related diseases.
Researchers have found that stimulating a specific bile acid receptor, FXR, may help prevent retinopathy of prematurity in premature babies. By targeting this receptor, the study aims to develop earlier and more effective treatments to protect their vision.
Researchers found that HER2-positive breast cancer patients with high levels of tumour infiltrating lymphocytes in residual disease have significantly shorter overall survival. High levels of TILs are associated with poorer outcomes, while lower levels are linked to improved survival rates.
Researchers at LSU Health New Orleans have identified a new drug target for triple-negative breast cancer, which lacks estrogen and progesterone receptors. The novel small molecule inhibitor NSC33353 works synergistically with doxorubicin to suppress the growth of TNBC cells.
Researchers have discovered that reduced TGFBR2 abundance is significantly associated with hepatocellular carcinoma (HCC) in patients with cirrhosis. An AI-based process accurately identified HCC tissue, confirming the biomarker's potential for early detection.
Researchers have found that two receptors on the surface of endothelial cells come together to enable new blood vessel growth. The discovery reveals a new connection between copper metabolism and angiogenesis, highlighting CTR1 as a potential therapeutic target for conditions like ischemic heart disease.
A University of Illinois study discovered that cadherin proteins can sense mechanical stress and alter cell communication, promoting tissue growth and tumorigenesis. The findings suggest a potential mechanism for preventing certain types of tissue growth by mutating cadherin molecules.
Patients treated with pyrotinib plus capecitabine had a lower risk of death and longer progression-free survival compared to those receiving lapatinib plus capecitabine. Pyrotinib is an irreversible tyrosine kinase receptor inhibitor targeting HER2, EGFR, and HER4.
Researchers at Queen Mary University of London confirmed HER2's role in predicting DCIS recurrence and response to adjuvant radiotherapy. HER2 overexpression is associated with a significantly increased risk of in situ recurrence.
Researchers identified nutraceuticals that mimic caloric restriction effects by modulating insulin-like growth factor 1 receptor signaling and sirtuin activity. These compounds promote longevity and healthspan without malnutrition.
A highly sensitive and selective ELISA for cetuximab determination in human plasma samples has been developed. The assay limit of detection was 0.0015 μg/mL and the effective working dynamic range was 0.005-6.25 μg/mL.
Researchers at Lobachevsky University have synthesized a multifunctional compound with anti-tumor properties, achieved through the combination of a photoactive organic dye, biological vector, linker, and hydrophilizing fragments. The new compound selectively accumulates in tumor tissues due to its ability to bind to growth factor recep...
Patients with advanced breast cancer who experience delayed disease progression have better quality of life outcomes compared to those whose disease progresses earlier. Delaying progression could be critical in improving health-related quality of life for patients with oestrogen receptor positive, HER2 negative advanced breast cancer.
A study found that NSCLC patients with EGFR mutations had longer overall survival when treated with tyrosine kinase inhibitors (TKIs) for leptomeningeal metastases, compared to those without TKI therapy. Chemotherapy was also associated with prolonged survival in these patients.
High total and saturated fat intake associated with greater risk of ER+PR+ breast cancer and HER2- disease. A high-fat diet increases BC risk, especially receptor-positive disease linked to saturated fat intake.
A research team from Japan has discovered that inhibiting IGF-IR activity decreases proliferation and motility of pancreatic cancer cell lines. This finding suggests a potential new approach for treating pancreatic cancer.
Researchers have identified an epidermal growth factor receptor aberrantly active in approximately a third of human pancreatic cancers, providing a new treatment target for this fatal disease. The discovery also holds promise for developing a blood or urine screening tool to detect pancreatic cancer earlier.
Researchers have produced the first detailed analysis of a hominoid-only gene, TBC1D3, which is linked to cancer. The study found that the protein helps turn on RAS, a protein active in a third of all human cancers. Further research aims to uncover the functions of human-only genes and their potential applications in fighting diseases.
Low-density lipoprotein (LDL) contributes to vascular diseases by activating VEGFR1, accelerating macrophage migration and plaque progression. The discovery could lead to a potential therapeutic target for medical applications.
Patients with metastatic colorectal cancer treated with EGFR-targeted monoclonal antibodies experience significant magnesium loss, affecting up to 97% of patients. The study suggests that identifying high-risk patients through patient characteristics could aid early intervention to prevent severe hypomagnesaemia.
Vanderbilt University Medical Center students James Peacock and Olga Weinberg have been awarded HHMI fellowships to pursue research in immunology and estrogen receptors. The fellowships will enable them to conduct academic-year-long research projects culminating in the Meeting of Medical Student Fellows.
Researchers have discovered a chemical messenger called fibroblast growth factor 18 (FGF 18) that regulates bone development in growing embryos. FGF 18 appears to coordinate both the lengthening and hardening of bones, which may lead to new understanding of diseases such as achondroplasia and osteoporosis.
UCSD researchers have discovered a natural regulatory protein, RGS-PX1, with dual roles in regulating cellular functions. The protein modulates both cell signaling and membrane trafficking, offering new avenues for disease research and potential targets for developing drugs to treat heart failure, hormone imbalances, and cancer.
UCSF researchers identified a signaling cascade that regulates steroidogenic factor 1, a nuclear receptor involved in sexual differentiation and stress response. The finding suggests a ligand-independent mechanism of action for SF-1, potentially explaining resistance to hormone therapies in certain cancers.
Researchers reveal that the Type III TGF-beta receptor plays a crucial role in transforming heart cells and forming valves, providing new insights into congenital heart defects. The discovery could lead to improved treatments for children with heart defects.
Researchers at Allelix Biopharmaceuticals Inc. have successfully cloned the GLP-2 receptor, which plays a crucial role in intestinal growth and nutrient absorption. The discovery provides valuable information on the specificity and action of GLP-2, a potential therapy for gastrointestinal disorders such as short bowel syndrome.
A team of Australian scientists has made a world-first discovery by describing the structure of a vital receptor found on the surface of body cells in all animals, including humans. This breakthrough has major implications for understanding growth and development, as well as diseases such as diabetes and cancer.
Researchers at Harvard Medical School have developed a new gene therapy technique that efficiently delivers genes to targeted cells by linking viruses with specific receptors. The technique, which uses a protein bridge made of growth factor EGF and ALV receptor proteins, allows for precise targeting of cell types, including cancer cells.
Researchers at Harvard Medical School found that a protein wireing the developing brain also prevents nerve cells from entering off-limits areas, and plays a role in blood vessel formation. This convergence of two processes may lead to new insights into cancer research and embryology.
Research on plasminogen-related growth factors has shed light on their role in mammalian development, tumorigenesis, and angiogenesis. The symposium explores the evolution of these growth factors and their interactions with other molecules, highlighting their importance in various biological processes.
Researchers at the University of Pennsylvania School of Medicine discovered that nerve growth factor induces cell death in some childhood brain tumor cells. The findings suggest a potential new treatment approach for these cancers, expanding scientists' understanding of NGF's role in development.